11:52 AM EDT, 06/26/2024 (MT Newswires) -- Sona Nanotech ( SNANF ) was last seen up 13% after the company on Wednesday said a detailed biomarker analysis of a recently reported pre-clinical melanoma study conducted at Dalhousie University shows that, beyond shrinking tumors on its own, Sona's Targeted Hyperthermia Therapy (THT) also stimulates the immune system to target and eliminate untreated (contralateral) tumors when combined with a standard immunotherapeutic drug.

Based on efficacy data achieved in two mouse cancer models (triple negative breast cancer and malignant melanoma), Sona is proceeding with safety and biocompatibility testing that will be required by regulating agencies ahead of human studies.

Sona also observed that the immunity generated by its gold nanorod-based THT therapy in its preclinical models is lasting, adding that "this is the proof of concept we were looking for."

The company's shares were last seen up $0.035 to $0.295 on the Canadian Securities Exchange.

Price: 0.30, Change: +0.04, Percent Change: +13.46